Establishing reference interval for thyroid-stimulating hormone in children below two-year ages in Pakistani population by Muneer, Siraj et al.
eCommons@AKU 
Department of Pathology and Laboratory 
Medicine Medical College, Pakistan 
7-31-2021 
Establishing reference interval for thyroid-stimulating hormone in 





Khadija N Humayun 
See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol 
 Part of the Pathological Conditions, Signs and Symptoms Commons, Pathology Commons, and the 
Pediatrics Commons 
Authors 
Siraj Muneer, Imran Siddiqui, Hafsa Majid, Lena Jafri, Khadija N Humayun, Sibtain Ahmed, and Aysha 
Habib Khan 
Annals of Medicine and Surgery 68 (2021) 102601
Available online 31 July 2021
2049-0801/© 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Cross-sectional Study 
Establishing reference interval for thyroid-stimulating hormone in children 
below two-year ages in Pakistani population 
Siraj Muneer a, Imran Siddiqui a, Hafsa Majid a,*, Lena Jafri a, Khadija Nuzhat Humayun b, 
Sibtain Ahmed a, Aysha Habib Khan a 
a Department of Pathology and Laboratory Medicine, Aga Khan University, Stadium Road, P.O. Box 3500, Karachi, 74800, Pakistan 
b Department of Pediatrics and Child Health, Aga Khan University, Stadium Road, P.O. Box 3500, Karachi, 74800, Pakistan   
A R T I C L E  I N F O   
Keywords: 
Thyroid stimulating hormone 
Reference interval 
Pakistan 
A B S T R A C T   
Introduction: Reference intervals (RIs) of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) are age, 
assay and population specific. Currently, the age and assay-specific RIs for TSH are not available for children 
under two years of age. This study aimed to establish reference intervals for serum concentrations of TSH and 
FT4 in healthy children aged 1–24 months as per CLSI C28-A3 guidelines. 
Methods: This prospective cross-sectional study was conducted in children from 1 to 24 months visiting the 
clinical laboratory for serum vitamin D testing but without any recent illness, hospitalization, medication and 
history of maternal thyroid diseases from August 2018 to March 2019 were invited to participate in the study. 
Serum TSH and FT4 were measured on ADVIA Centaur (Siemens Diagnostics, US), using chemiluminescence 
immunoassay. Kolmogorov–Smirnov test assessed normality of the data and RIs based on central 95% of the 
population were established using the non-parametric approach. 
Results: After excluding one subject with confirmed congenital hypothyroidism, a total of 131 children were 
included in the study. The median (IQR) age of the study subjects was 12 months (11), and majority 78 (59.5%) 
were boys. The RIs were established using non-parametric approach as the data was not normally distributed. 
Reference interval for TSH was 0.73–4.94 μIU/mL and for FT4 was 0.81–1.51 ng/dl. 
Conclusion: We established assay-specific RIs for serum TSH and FT4 in children aged 1–24 months in our 
population. The RIs were slightly lower from RIs developed on other platforms in different population.   
1. Introduction 
Congenital hypothyroidism (CH) occurs in approximately 1: 2,000 to 
1: 4,000 newborns worldwide [1]. However, Pakistan’s estimated inci-
dence is much higher, approximately 1 in 1600 live births [2]. The CH is 
one of the most common preventable causes of mental retardation [3]. 
With early detection through newborn screening (NBS) and prompt 
treatment with levothyroxine, intellectual disability can be prevented 
[4]. 
Screening for CH is performed by dried blood spot screening of 
Thyroid Stimulating Hormone (TSH) within 48–72 h of birth. A positive 
screening test is confirmed by measuring serum TSH and free thyroxine 
(FT4) levels [5]. For a better intellectual outcome of patients with CH, 
thyroid hormone concentrations should be normalized rapidly (within 
the first two weeks after treatment initiation) and then maintained [6]. 
According to the American Academy of Pediatrics Guidelines, for 
optimal thyroxin replacement, serum TSH and FT4 measurements 
should be performed at regular intervals. More frequent monitoring is 
recommended when compliance is questioned, abnormal values are 
obtained, or dose or medication source has been changed [7]. 
Appropriate age, population and assay-specific TSH reference in-
tervals (RIs) are essential for optimal treatment outcomes. The RIs of 
TSH are wider in neonates as compared to infants and other pediatric 
age groups, so if one uses the same neonatal RIs to interpret the results of 
children older than one month and vice versa, it will lead to under or 
over the treatment of the patient, leading to adverse effects and un-
necessary repeated testing. 
Guidelines by the National Academy of Clinical Biochemistry 
recommend that each laboratory determine their age and assay-specific 
TSH-RIs to ensure appropriate interpretation [8]. There was a need to 
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establish RIs for our population in children under two years to improve 
clinical care. This study was conducted to establish RIs for serum TSH in 
healthy children under two years of age, as per the Clinical Laboratory 
Standards Institute (CLSI), C28-A3 guidelines. We also compare estab-
lished cutoffs with reported reference data [9]. 
2. Material and methods 
A prospective cross-sectional study was conducted at the Section of 
Chemical Pathology, Department of Pathology and Laboratory Medi-
cine, AKUH Karachi Pakistan after approval from Aga Khan University 
Hospital’s Ethics Review Committee. The study has been reported in line 
with the STROCSS criteria [10]. This study is registered on ‘Clin-
icaltrials.gov’ and the unique Identifying number is NCT04877665. 
Healthy children from 1 to 24 months visiting the clinical lab for serum 
vitamin D testing from August 2018 to March 2019 were invited to 
participate in the study. Their health status was determined by asking 
questions related to recent illness, hospitalization, medication and 
maternal history of thyroid-related diseases (Appendix 1), after 
informed consent from their parents/guardian. Children with recent 
abnormal total leucocyte or neutrophil count in the medical record or 
positive microbial cultures, history of any diagnosed disease or infec-
tion, history of hospitalization during the previous four weeks, 
congenital hypothyroidism or transient congenital hypothyroidism, 
history of maternal thyroid illness, or any medications with potential 
influences on the thyroid function, such as amiodarone, anti-epileptic 
drugs, glucocorticoids were excluded, shown in Fig. 1. 
2.1. Biochemical analysis 
Residual serum samples received for serum vitamin D testing were 
utilized to measure serum TSH and FT4. Serum TSH and FT4 were 
analyzed on ADVIA® Centaur™, Siemens Diagnostics USA using 
chemiluminescence immunoassay technique. The ADVIA Centaur TSH- 
Ultra (3rd generation) assay’s analytical measurement range was from 
0.010 to 150 μIU/mL (1uIU/mL = 1mIU/L), while for FT4 was 0.1–12.0 
ng/dl. The TSH assay standardization was traceable to the World Health 
Organization (WHO) 3rd International Standard for human TSH (IRP 
81/565), so results were not procedure dependent. Three-level quality 
control materials were run with each batch of samples for internal 
quality control. External proficiency was assured by analyzing samples 
from the College of American Pathologists thrice per year, throughout 
the study period, and all external proficiency surveys during the study 
period were acceptable. The manufacturer provided TSH RIs were for 
>2 years to adult age-group only, while the manufacturer provided RI 
for FT4 for children of 1–23 months was 0.94–1.44 ng/dl. 
The RIs for children aged 1–24 months were established using the 
CLSI, C28-A3 guidelines ’Defining, Establishing, and Verifying Refer-
ence Intervals in the Clinical Laboratory; Approved Guideline Third 
Edition’. These guidelines recommend using a sample size of at least 120 
specimens, to obtain both an RI estimate and a 90% confidence interval 
for it without making any assumption about the population distribution. 
The sample size was kept at 132, after adding an attrition rate of 14%. 
Ethical approval was sought and obtained from the institution’s Ethical 
Review Committee before the study’s commencement (ERC number: 
5255-Pat-ERC-18). 
2.2. Statistical analysis 
The EP evaluator version 10 and SPSS version 21 were used for data 
analysis. Kolmogorov–Smirnov test assessed the normality of the data. 
The RIs based on central 95% of the population were established using 
the nonparametric approach. In the nonparametric method, the refer-
ence interval is calculated, making no assumption about the population 
Fig. 1. Flowchart of subjects included in the study.  
Table 1 
Reference interval for thyroid stimulating hormone and free T4 in children under 2 Years of age (n = 131).    
Range Median P-value Lower Limit (95% CI) Upper Limit (95% CI) 
TSH (μIU/mL) Male (n ¼ 78) 0.61–4.95 1.87 0.096 0.67 (0.55–0.81) 4.31 (3.81–4.86) 
Female (n ¼ 53 0.86–6.91 2.13 0.75 (0.61–0.92) 5.75 
4.70–7.03 
Both (n ¼ 131) 0.61–6.91 1.94 0.73 (0.61–0.86) 4.94 
4.41–6.91 
FT4 (ng/dl) Male (n ¼ 78) 0.68–1.73 1.09 0.878 0.80 (0.76–0.84) 1.47 
1.40–1.54 
Female (n ¼ 53) 0.75–1.53 1.09 0.77 (0.70–0.83) 1.43 
1.37–1.50 
Both (n ¼ 131) 0.68–1.73 1.09 0.81 (0.68–0.84) 1.51 
1.42–1.73  
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distribution shape. The median age of subjects, TSH and FT4 levels were 
calculated. For assessing differences in the male and female gender, 
Students’ t’ test was applied, taking p-value <0.050 as significant. 
Spearman’s test computed the correlation between age, TSH and FT4 
levels. 
3. Results 
A total of 132 children were included in the study; one subject with 
confirmed congenital hypothyroidism (CH) was excluded from the 
study, shown in Fig. 1. The TSH and FT4 values of 131 subjects were 
included to establish the RIs. The median (IQR) age of the study subjects 
was 12 (11) months, and 78 (59.5%) were male. The median (95% in-
tervals) of serum TSH and free T4 were 1.94 (0.61–6.91) μIU/L and 1.09 
(0.68–1.73) ng/dL respectively. 
The data was not normally distributed, so the non-parametric 
approach was applied to establish RIs. Reference interval based on 
central 95% of the population for TSH is 0.73–4.94 μIU/mL and for FT4 
is 0.81–1.51 ng/dL. The RIs for Male and female were not significantly 
different for both TSH (p-value 0.096) and FT4 (p-value 0.878), 
(Table 1). 
Both TSH (p value 0.000, r = − 0.339) and FT4 (p value 0.006, r =
− 0.239) levels significantly correlated with age, the levels decreasing 
with increasing age, Fig. 2(a) and (b). 
Subjects were divided into three age groups, Group I; <6 months, 
group II; 7–12 months and group III; 13–24 months. The mean difference 
between TSH and FT4 levels between these age groups was statistically 
significantly (p-value 0.001 and p-value <0.001) respectively (Table 2). 
4. Discussion 
CH is one of the most common preventable causes of mental retar-
dation and satisfies all the criteria for being included in an NBS program 
Fig. 2(a). Age-wise distribution of Thyroid Stimulating Hormone levels in study subjects.  
Fig. 2 (b). Age-wise distribution of Free T4 levels in study subjects.  
Table 2 
Distribution of Thyroid Stimulating Hormone and Free T4 in different age 
groups (n = 131).  
- <6 months 7–12 months 13–24 months p value 
n 37 34 60 – 
TSH (uIU/ml) 2.72 ± 1.3 2.12 ± 1.06 1.88 ± 0.88 0.001 
FT4 (ng/dl) 1.19 ± 0.2 1.05 ± 0.14 1.06 ± 0.14 <0.001  
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[11]. After a CH diagnosis, all children should be treated and frequently 
monitored using serum TSH and FT4. For accurate monitoring, appro-
priate RIs must be used for reporting the patient’s results. The RIs of TSH 
is affected by age, gender, population, iodine intake and assay used [8]. 
This study was conducted to establish assay and population-specific 
RIs for children aged 1–24 months, as RIs for this age group were not 
available. The RIs determined by the present study for TSH and FT4 
were 0.73–4.94 μIU/mL and 0.81–1.51 ng/dl, respectively. No studies 
have reported assay and population-specific RIs for the Pakistani, Indian 
or even South Asian population to the best of our knowledge. However, 
the clinical practice guidelines for screening, diagnosis and management 
of CH by the Indian Society for Pediatric and Adolescent Endocrinology 
has recommended the RIs determined by Lem AJ et al. in a European 
population of Netherlands [6,12]. The RIs determined by Lem AJ et al. 
for 1–3 months, 3–12 months, 1–5 years for TSH were 0.58–5.57 mIU/L, 
0.57–5.54 mIU/L, 0.56–5.41 mIU/L and FT4 were 1.04–3.4 ng/dl, 
1.1–2.4 ng/dl, 1.1–2 ng/dl respectively. These RIs are slightly wider 
than the RIs established in our population, the difference could have 
been due to a different assaying platform utilized, i.e. Advia Centaur 
immunoassay analyzer (Siemens Diagnostics) used in current study 
while Vitros ECI immunoassay analyzer (Ortho Diagnostics) used by 
Lem AJ et al. When comparing with RIs developed on a similar platform 
as used in the present study, i.e. Advia Centaur immunoassay analyzer 
(Siemens Diagnostics), but different population we observed that the RIs 
for our population were slightly lower as compared to Caucasians and 
Asians shown in Table 3 [13–15]. Loh TP et al. established TSH RIs in 
Asian children, including 59% Chinese and 13% Indians using Advia 
Centaur immunoassay in 82% of the subjects [15]. 
The trends of the reference values obtained from this study showed 
slight differences from those obtained from the other studies, which 
might be explained by different analytical assays, different tools used for 
statistical analysis, differences in ethnicity, population or geographic 
derived covariates such as lifestyle, salt iodination, and nutrition. These 
findings further endorse that there was a dire need to develop assay- 
specific RIs for our population. The RIs established in subjects from 
the same geographic area, using the same analyzer used in routine work, 
is definitively better. 
We observed no significant difference in TSH or FT4 RIs between 
male and female in the present study. However, RIs significantly 
correlated with age, i.e. decreasing RIs with increasing age, Table 2. 
Similar findings were reported by Kratzsch J. et al. which assessed the 
association between TSH, age, BMI, Number of blood leucocytes, gender 
and observed that only age was a relevant predictor of TSH variation 
with 8% [16]. Therefore, these findings suggest that the establishment of 
age-dependent reference intervals is mandatory for TSH and larger, 
prospective studies should be performed to address these findings. 
This is the first study from Pakistan reporting the RIs for TSH and FT4 
for children aged 1–24 months using the Advia® Centaur™ assay. One 
of the strengths of this study was the prospective study design. Col-
lecting pediatric healthy subjects samples is especially difficult, and 
most of the studies reported in the literature have established TSH and 
FT4 RIs for pediatric age groups using retrospective data analysis. Our 
study presents some limitations, including small sample size, non- 
partitioning of the data into smaller age groups, and due to limited 
availability of funds thyroid, antibody testing of mother and child could 
not be performed. A more extensive prospective study needs to be 
planned with further age categorization for a more generalizable data. 
5. Conclusion 
We established assay-specific RIs for serum TSH and FT4 in children 
aged 1–24 months in our population. The RIs developed differed slightly 
from RIs developed using other platforms in different population. The 
TSH and FT4 were significantly associated with age, requiring that 
validated RIs developed for our population should be used for assessing 
TSH and FT4 results in children under two years of age. However same 
RIs of TSH and FT4 can be used for both male and female children. 
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Table 3 
The RIs determined by Kapelri et al. (12), Hubner et al. (13) and Loh et al. (14) using Advia Centaur Immunoassay analyzer.  
Study Our Study Kapelari et al. Hubner et al. Tze Ping Loh et al. 
Country Pakistan Austria Germany Singapore 
Analyzer Advia Centaur Advia Centaur Advia Centaur Advia Centaur and Ortho Vitros 5600 
Age 1–24 Months 1m–12 m 1y-2y 1m-1y 1y-5y 2m-4y 
FT4 (ng/dl) 0.79–1.34 0.92–1.74 0.92–1.61 0.88–1.62 0.88–1.47 – 
TSH (μIU/ml) 0.733 4.945 1.30–7.09 1.0–5.42 0.30–5.88 1.0–5.42 0.74–5.68  
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